RadChem 2022



Contribution ID: 1117

Type: SPA

Development of 211At-Radiopharmaceuticals for Pretargeted Radioimmunotherapy of Disseminated Cancer

Tuesday, 17 May 2022 16:35 (5 minutes)

To enhance the therapeutic efficacy of radioimmunotherapy of cancer, several pretargeting strategies have been developed. In pretargeted radioimmunotherapy, the tumour is pretargeted with a modified monoclonal antibody that has affinity for both, tumour antigen and radiolabeled carrier. A big challenge in cancer treatment is the elimination of occult disseminated tumour cells, in this context the alpha emitter 211At has drawn attention due to its physicochemical characteristics. This project aims to design new molecules for pretargeting applications based on the Diels Alder click chemistry system (Tetrazine (Tz)/Trans-cyclooctene (Tco)) using 211At as radionuclide, and to evaluate these substances to optimize the pharmacokinetics.

Presenter: TIMPERANZA, Chiara (University of Gothenburg) **Session Classification:** Student Poster Appetizers